Initiated multiple Phase 1b expansion cohorts to determine the RP2D of ORIC-114 in NSCLC patients with EGFR exon 20, HER2 exon 20, or EGFR atypical mutations
ISELIN, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced that it has closed its previously announced private placement with Syntone Ventures, LLC, an existing stockholder, for upfront gross proceeds of approximately $5.0 million from the issuance and sale of shares of the Company’s common stock and accompanying warrants, before deducting offering expenses. In addition, Outlook Therapeutics has the potential to receive additional gross proceeds of up to $8 million upon the full cash exercise of the warrants issued in the private placement, before deducting offering expenses.
Read this article:
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million
MISSISSAUGA, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc. (“BioSyent Pharma”), has extended its Exclusive License and Distribution Agreement with its European partner for the RepaGyn® and Proktis-M® products, extending BioSyent Pharma’s exclusive Canadian rights to these products until 2032.
See more here:
BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement
Topline results from Phase 1b study of LTI-03, a novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected to be reported in the third quarter of 2024
See the article here:
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has granted Fast Track designation1 for the Company’s investigational glioma imaging product, TLX101-CDx (Pixclara™2, 18F-floretyrosine or 18F-FET).
Excerpt from:
TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation
ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years
Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024
Here is the original post:
Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024
TURKU, Finland and BOSTON, April 16, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (“Faron” or the “Company”) (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, today announces ongoing plans and activities for the coming months following the recent announcement of the proposed appointment of Dr. Juho Jalkanen as Chief Executive Officer, effective 1 May 2024.
Read the original post:
Faron Confirms Plans for the Coming Months Under New Leadership
Tokyo, Japan and Cambridge, UK, 16 April 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – has been notified by its partner Neurocrine Biosciences Inc. (“Neurocrine”; Nasdaq: NBIX) that NBI-1117568, an oral selective muscarinic M4 receptor agonist being advanced in Phase 2 clinical trials by Neurocrine for the treatment of schizophrenia and other neuropsychiatric disorders, has successfully completed a long-term preclinical toxicity program that meets US FDA requirements to allow for safe, chronic (i.e. long-term) dosing in future clinical trials. The achievement of this important safety development milestone triggers a $15 million payment to Nxera from Neurocrine.
Read the original here:
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
U.S. Biotechnology Market Size to Increase USD 1.79 Trillion by 2033 BioSpace
Follow this link:
U.S. Biotechnology Market Size to Increase USD 1.79 Trillion by 2033 - BioSpace
6 biotechnology universities in the USA developing young talent Labiotech.eu
View post:
6 biotechnology universities in the USA developing young talent - Labiotech.eu
Lee Hsien Loong presided over efforts to retool Singapore's export-driven economy by focusing on advanced ... NBC Right Now
Read more from the original source:
Lee Hsien Loong presided over efforts to retool Singapore's export-driven economy by focusing on advanced ... - NBC Right Now
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates GlobeNewswire
Follow this link:
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates - GlobeNewswire
Lee Hsien Loong presided over efforts to retool Singapore's export-driven economy by focusing on advanced ... pdclarion.com
See the original post here:
Lee Hsien Loong presided over efforts to retool Singapore's export-driven economy by focusing on advanced ... - pdclarion.com
BIO's top lobbyist exits, signaling reorganization - STAT STAT
More here:
BIO's top lobbyist exits, signaling reorganization - STAT - STAT
BIO's top lobbyist heads out the door FiercePharma
Continued here:
BIO's top lobbyist heads out the door - FiercePharma
Biotech Rebound Could Boost This ETF ETF Trends
Continued here:
Biotech Rebound Could Boost This ETF - ETF Trends
Technion team discovers important adaptive strategy of the microbiome, impacting immune system The Jerusalem Post
Go here to read the rest:
Technion team discovers important adaptive strategy of the microbiome, impacting immune system - The Jerusalem Post
Targeting aging and age-related diseases with vaccines Nature.com
Read more:
Targeting aging and age-related diseases with vaccines - Nature.com
After the Smoke Clears: Scars on the Immune System The Scientist
Read the rest here:
After the Smoke Clears: Scars on the Immune System - The Scientist